Finanzen von Akari Therapeutics PLC (AKTX)AKTXAkari Therapeutics PLC

Evaluating the bottom line, Akari Therapeutics PLC maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -140.09%, provide a clear picture of how effectively AKTX converts its operational activities into shareholder value.

In the context of the broader market, AKTX competes directly with industry leaders such as BIVI and CMMB. With a market capitalization of $20.83M, it holds a leading position in the sector. When comparing efficiency, AKTX's gross margin of N/A stands against BIVI's N/A and CMMB's N/A. Such benchmarking helps identify whether Akari Therapeutics PLC is trading at a premium or discount relative to its financial performance.

The company has shown a significant decrease in net income, with losses increasing to -14,455,000 USD in Q1 2026, and a current ratio of 0.60, indicating potential liquidity issues.